Johnson Investment Counsel Inc. Has $3.22 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Johnson Investment Counsel Inc. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,947 shares of the medical research company’s stock after buying an additional 27 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Thermo Fisher Scientific were worth $3,222,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TMO. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. Cohen Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock valued at $167,271,000 after purchasing an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co lifted its stake in shares of Thermo Fisher Scientific by 6,773.5% in the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after purchasing an additional 283,810 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research note on Thursday, July 24th. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research note on Wednesday. Finally, UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $593.43.

Thermo Fisher Scientific Price Performance

TMO stock opened at $524.95 on Monday. The stock has a 50-day moving average price of $488.68 and a two-hundred day moving average price of $447.49. The stock has a market cap of $198.23 billion, a PE ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last quarter. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.